Maze Therapeutics Inc. (MAZE)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
Maze Therapeutics, Inc. (MAZE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $1.15 per share a year ago.
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.
Chief Medical Officer Harold Bernstein sold 15,000 company shares for a transaction value of ~$442,000 at around $29.46 per share on April 1, 2026. This disposition represented 100% of Harold Bernstein's direct Common Stock holdings, reducing his direct ownership of Common Stock to zero.
Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop
I am initiating coverage on Maze Therapeutics (MAZE) with a "Buy" rating following positive phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease. MZE829 achieved a 35.6% mean reduction in proteinuria, exceeding the ≥30% uACR threshold required for clinical relevance and potential regulatory advancement. Despite a 37% stock drop post-data, I view the market reaction as overblown given the program's success and planned pivotal trial initiation.
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)
The heavy selling pressure might have exhausted for Maze Therapeutics, Inc. (MAZE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Maze Therapeutics: An Innovative, Nature-Driven Platform
Maze Therapeutics leverages its Compass platform to translate human genetic insights into de-risked, high-probability drug candidates. MZE829 targets APOL1-mediated kidney disease with a dual inhibition strategy, potentially surpassing Vertex's first-mover approach; Phase 2 HORIZON data is expected in Q1 FY2026. MAZE's pipeline includes MZE782 for phenylketonuria and CKD, plus a promising 'skinny gene' obesity program targeting nutrient absorption.
Maze Therapeutics, Inc. (MAZE) Presents at Jefferies London Healthcare Conference 2025 Prepared Remarks Transcript
Maze Therapeutics, Inc. ( MAZE ) Jefferies London Healthcare Conference 2025 November 20, 2025 7:00 AM EST Company Participants Jason Coloma - CEO & Director Presentation Jason Coloma CEO & Director Good morning, everyone. I'm Jason Coloma.
Maze Therapeutics CEO Jason Coloma on how the new biotech is taking on Kidney disease
(OPTIMIZED VIDEO SPECIFIC DESCRIPTION)
Maze Therapeutics, Inc. (MAZE) Discuses On MZE782 Phase 1 Healthy Volunteer Trial Results Call (Transcript)
Maze Therapeutics, Inc. (NASDAQ:MAZE ) MZE782 Phase 1 Healthy Volunteer Trial Results Conference September 11, 2025 08:30 AM ET Company Participants Amy Bachrodt Jason Coloma - CEO & Director Harold Bernstein - President of Research & Development and Chief Medical Officer Misbah Tahir - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Tyler Van Buren - TD Cowen, Research Division Laura Chico - Wedbush Securities Inc., Research Division Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division Julian Harrison - BTIG, LLC, Research Division Presentation Operator Good morning.
Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut
Shares of Maze Therapeutics rose nearly 1% in their Nasdaq debut on Friday, valuing the kidney disease drug developer at $690.37 million.
Biotech firm Maze Therapeutics raises $140 million in US IPO
Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that could make the kidney disease drug developer the first U.S. biotech listing this year.
Maze Therapeutics targets up to $728 mln valuation in US IPO
Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States.
Maze Therapeutics Seeks IPO For Trials Ramp-Up
Maze Therapeutics aims to raise $100 million in an IPO to fund clinical trials for its kidney and related disease treatments. The company's lead candidate, MZE829, is in Phase 2 trials for APOL1 kidney disease, with promising Phase 1 results. Maze has strong financial backing and a significant partnership with Shionogi & Co., positioning it well for future development.
